WCCT Global LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$495,390	3
2023	Research	$3,146,141	11
2022	Research	$3,039,878	14
2021	Research	$7,715,333	48
2020	Research	$1,056,591	7
2019	Research	$524,096	3

Breakdown

Who paid Research payments · program years 2019–2024

Eli Lilly and Company $9,540,204 79 payments
Amgen Inc. $5,914,541 4 payments
AstraZeneca Pharmaceuticals LP $521,840 1 payment
Allergan Inc. $844 2 payments

Studies the money was for Research payments · program years 2019–2024

Single-Blind; Single Dose; 2-Arm; Parallel Group to Determine Pharmacokinetic Equivalence $2,760,965 2 payments
Healthy Volunteer Study - ABP 654 $2,490,280 1 payment
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3819469 $1,575,182 2 payments
A Phase I Participant- and Investigator-Blind Single-Center Study to Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of Ly3871801 in Healthy Asian and Non-Asian Participants $1,528,178 2 payments
A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3561774 $1,489,644 6 payments
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-Ml and 2-Ml Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-Ml and 2-Ml Prefilled Syringes in Healthy Participants $932,252 2 payments
The Effect of Imlunestrant on Cyp2c8, Cyp2c19, Cyp2d6, P-GP, and BCRP Activity and the Effect of P-GP Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-Childbearing Potential $871,524 2 payments
ABP 654 Phase 1 Healthy Volunteer Study $663,296 1 payment
A Single-Ascending Dose Safety Tolerability and Pharmacokinetic Study of Ly3462817 in Healthy Japanese and Non-Japanese Participants $560,896 1 payment
A Phase 1, Randomized, Investigator- and Participant-Blind, Placebo-Controlled Study of Ly3473329 Multiple-Ascending Dosing in Healthy Japanese Participants $534,442 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.